Last reviewed · How we verify

Placebo (PCB)

New York State Psychiatric Institute · Phase 3 active Small molecule

Placebo produces therapeutic effects through patient expectation and the psychobiological response to receiving treatment, rather than through a pharmacologically active ingredient.

Placebo produces therapeutic effects through patient expectation and the psychobiological response to receiving treatment, rather than through a pharmacologically active ingredient. Used for Control arm in phase 3 clinical trials (non-therapeutic use).

At a glance

Generic namePlacebo (PCB)
Also known asPCB or 0 mg, 0 mg
SponsorNew York State Psychiatric Institute
ModalitySmall molecule
PhasePhase 3

Mechanism of action

Placebo effects arise from complex neurobiological mechanisms including expectation, conditioning, and endogenous neurotransmitter release. In clinical trials, placebos serve as control comparators to distinguish true drug efficacy from placebo response. The magnitude of placebo effect varies by condition, route of administration, and patient belief.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: